tada, I'm sure many agree with what you say under the present circumstances.

"On the other hand a smaller company that wants to introduce a disruptive technology and has some financial backing could have a field day with APB and end up making a handsome ROI."

But why wouldn't Shenzhen Hepalink, with a market cap of $3.5 B CAN, owning ~35% of the RVX stock and having a licence to manufacture Apabatelone, the magic drug, not take the initiative and do something with it? That's the part of our story that makes no sense. They will never allow Apabetalone to fall into other hands. But are they able to take up the Apabetalone baton and do something with it on their own if push comes to shove? Has their licence for Apabetalone allowed them all along (for all our sakes) to take Apabetlone to bigger heights in their part of the world with a population of ~1.4 billion people without interference from Resverlogix because the company failed to do so?

Just asking  ... Koo